Phaseline

Companies › Just-Evotec Biologics

Just-Evotec Biologics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Infectious disease, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JST-018
Combination of 3 monoclonal antibodies
–Phase 1Antiviral DrugNov 2026
JST-010
Monoclonal antibody
–Phase 1Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy AdultsApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07595458JST-018Phase 1Antiviral DrugInfectious diseaseNov 2026
NCT06943378JST-010Phase 1Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy AdultsOtherApr 2027

From the company's SEC filings

Cash and short-term investments of 397m EUR on 2024-12-31; operating cash flow positive

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.